<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 24, 1997
SUGEN, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-24814 13-3629196
(State of jurisdiction) (Commission File No.) (IRS Employer
Identification No.)
351 Galveston Drive
Redwood City, California 94063
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 306-7700
<PAGE>
Item 5. Other Events.
- -------------------------------------------------------------------------------
On October 24, 1997, SUGEN, Inc. (the "Company") announced the filing
with the Securities and Exchange Commission of a registration statement in
connection with the proposed follow-on public offering of 2,500,000 shares of
its Common Stock, all of which are being sold by the Company. In addition,
the Company has granted the underwriters an option to purchase an additional
375,000 shares of Common Stock to cover over allotments, if any.
2.
<PAGE>
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
- -------------------------------------------------------------------------------
(a) Financial Statements.
None.
(b) Pro Forma Financial Information.
None.
(c) Exhibits.
99.1 Press Release, titled "SUGEN, Inc. Announces Filing of Registration
Statement," dated October 24, 1997.
3.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SUGEN, Inc.
Dated: October 24, 1997 By: /s/ Christine E. Gray-Smith
----------------------------
Christine E. Gray-Smith
Vice President, Finance
4.
<PAGE>
Contacts: D. Kevin Kwok Burns McClellan, Inc.
Director, Business Development Regan Codner
and Acting Director of Investor Relations (investors)
SUGEN, Inc. (212) 213-0006
(650) 306-7700 Audra Nass (media)
[email protected] (415) 352-6262
For Immediate Release
SUGEN, INC. FILES TO SELL 2.5 MILLION SHARES OF COMMON STOCK
Redwood City, CA October 24, 1997 - SUGEN, Inc. (Nasdaq: SUGN) today announced
that it has filed with the Securities and Exchange Commission a registration
statement in connection with the proposed follow-on public offering of 2,500,000
shares of its Common Stock, all of which are being sold by the Company. In
addition, the Company has granted the underwriters an option to purchase an
additional 375,000 shares of Common Stock to cover over allotments, if any. The
offering will be lead managed by Hambrecht & Quist, Lehman Brothers and UBS
Securities.
A preliminary prospectus relating to these securities may be obtained when
available from Hambrecht & Quist LLC, One Bush Street, San Francisco, CA
94104, phone: (415)439-3423, Lehman Brothers, Three World Financial Center,
New York, NY 10285, phone: (516)254-7106; or UBS Securities LLC, 299 Park
Avenue, New York, NY 10171, phone: (212)821-4504.
A registration statement relating to these securities has been filed with the
Securities and Exchange Commission but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy nor shall
there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any state or jurisdiction.
SUGEN, Inc. is a biopharmaceutical company focusing on the development of new
classes of small molecule drugs which interact in a specific manner with
different members of the tyrosine kinase, serine-threonine kinase and tyrosine
phosphatase families of signal transduction molecules, and their signalling
pathways. These pathways are involved in a number of human diseases including
cancer and diabetes, as well as disorders of the body's immune defenses and
neurological systems. SUGEN has SU101 (a PDGF receptor inhibitor) in Phase II
clinical trials for the treatment of malignant gliomas and other cancers, SU5271
(an EGF receptor inhibitor) in Phase I clinical studies for the treatment of
psoriasis, and recently initiated a Phase I trial for SU5461, a Flk-1/KDR
angiogenesis inhibitor for the treatment of solid tumor cancers. The Company
has research and development collaborations with Zeneca, ASTA Medica and
Allergan.
Additional written materials and press releases regarding SUGEN are available
through the SUGEN Fax-On-Demand Information Service by dialing 1-888-329-4699.
# # #
